Dr. Stéphane Huberty, MD is the CEO and has a proven business record as a manager and entrepreneur over the last 20 years.  CuraVac is focused on bringing new vaccine strategies developed by Prof. J. Edwin Blalock of the University of Alabama at Birmingham (UAB) to the market. 

CuraVac owns the patented production technique for the vaccines.  The first vaccine, the MG therapeutic vaccine is also patented by CuraVac and ready for Phase 1A human trials. In November 2009 the MG therapeutic vaccine received the orphan drug status in Europe. 

This vaccine is the first in a series. It will be tested on humans suffering from the orphan disease Myasthenia Gravis (MG). While not widely known, MG affects one in five to seven thousand (there are about 200,000 diagnosed cases with 15,000 new cases each year in USA, Europe and Japan). MG pathology is clearly understood and the curative action of our vaccine can easily be assessed in a simple blood test making it an excellent development model.  Based on the price of current treatments, the market for the MG therapeutic vaccine is estimated to be over EUR 5 billion (5 bn €) during the first 7 years following its introduction.

Further CuraVac therapeutic vaccines will be developed for the treatment of other autoimmune diseases, including Multiple Sclerosis (MS, 15/10,000, a potential market of 50 bn €), Diabetes (75/10,000, a potential market of 5 bn € / year). Autoimmune diseases afflict more than 5 % of the population, a market well over 50 bn € per year.

Beside the human aspects of helping to cure several autoimmune diseases, investors can expect high return on investment.